Skip to content

A Multi-Institutional Study on West Nile Virus Uveitis: Treatment, Complications, and Long-Term Outcomes.

Sep 2026 · Retina · 0 citations
Medicine

TL;DR

WNV uveitis often has a self-limited course but can be intractable in some patients, with long-term control needed for CME and retinal vasculitis with systemic IMT.

Abstract

Purpose

West Nile virus (WNV) can cause anterior/intermediate uveitis with characteristic multifocal chorioretinal lesions. Literature on acute manifestations is robust; however there is limited data describing the full spectrum of uveitic manifestations of WNV, treatments in the acute and chronic phase, as well as long-term sequelae.

Methods

A retrospective observational study from three academic uveitis practices. Patients diagnosed with WNV based on serologic and imaging findings were selected; data collected included demographics, ocular and systemic co-morbidities, ophthalmic examination findings, and treatment.

Results

Eleven patients were included between 2015 to 2023, with a mean follow-up of 128 weeks (∼ 2.5 years). The average patient was a 60-year-old Caucasian (64%) woman (55%); 27% of patients had diabetes. Fifty-five percent presented with 20/20-20/40 Snellen visual acuity. Importantly, 73% of patients in this cohort were hospitalized due to encephalitis or meningitis. Acute findings included anterior inflammation (8 [36.4%] eyes), vitreous inflammation (9 [40.9%] eyes), cystoid macular edema (CME) (6 [27.3%] eyes), non-occlusive retinal vasculitis (5 [22.7%]), and 1 (4.5%) eye with occlusive retinal vasculitis. Two (9.1%) eyes developed secondary peripheral retinal neovascularization requiring anti-vascular endothelial growth factor treatment or laser panretinal photocoagulation. Eight (36.4%) eyes were initially treated with systemic steroids, and 4 (18.2%) eyes required immunomodulatory therapy (IMT) for recurrent CME and retinal vasculitis.

Conclusion

WNV uveitis often has a self-limited course but can be intractable in some patients, with long-term control needed for CME and retinal vasculitis with systemic IMT. Ophthalmologists must be aware of the rarer complications that may require intervention.

View source

Similar papers

Sep 2026

Prevalence and Long-Term Incidence of Ocular Manifestations in Sarcoidosis: A Large Nationwide Population-Based Study.

PURPOSE Ocular involvement causes major vision-threatening morbidity in sarcoidosis. Population-based evidence on the full ocular spectrum, long-term incidence, and organ-specific patterns remains limited. METHODS Nationwide 1:1 matched case-control study with a longitudinal retrospective cohort component, using the...

U. Shani, Y. Patt, S. Ehrenberg et al. · 0 citations
Review Open access Sep 2026

Early Clinical Manifestations and Visual Prognosis of Japanese Patients with Norrie Disease: A Case Series and Literature Review

Combined analysis of the cohort and the literature review identified 29 Japanese patients from 19 families and demonstrated that most already had advanced bilateral retinal detachment within the first two months of life, leaving limited opportunities for effective intervention.

Takuma Futami, Yuko Higashi, Itsuka Matsushita et al. · 0 citations
Review Oct 2026

Severe Dupilumab-Associated Ocular Surface Disease: Multicenter Experience and Management Considerations.

Severe DAOSD may be underrecognized, as mild early symptoms can delay referral and allow progression to advanced, vision-threatening complications and early ophthalmologic evaluation and timely referral are essential to prevent irreversible ocular surface damage and vision loss.

Allison Y. Kufta, Syeda Zainab Kazmi, Seyyedehfatemeh Ghalibafan et al. · 0 citations
Open access Sep 2026

Immunosuppressive and biologic agents in the treatment of uveitis due to systemic disease

Purpose: To determine treatment strategy, visual outcome, adverse effects and therapeutic response to immunomodulation in non-infectious posterior uveitis (PU). Design: Retrospective study on 125 patients over 3 years with minimum follow up of 3 years. Materials and Methods: Retrospective study on 125 patients with Non...

Venkat Meghana Bhimanadham, Radha Annamalai, Balaji Chilukuri et al. · 0 citations
Open access Sep 2026

Ocular Manifestations and Visual Outcomes of Patients with Giant Cell Arteritis

Background: Ocular involvement in giant cell arteritis (GCA) is common, yet there is limited literature addressing its specific ocular manifestations and their impact on visual outcomes. The objective was to evaluate the incidence of visual involvement, treatment, relapse rate, and visual outcome in patients with GCA....

Timothy Do, G. Gulati, Han Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.